Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

PRESS: Sandoz Enbrel Copycat Next Biosimilar To Get Panel Treatment (Scrip)

Related Content

How To Reduce the Risk of Copyright Infringement When Using Generative AI To Write Code

Coding with AI in an Open-Source World

In re Cellect: Federal Circuit Opens New Path for Double Patenting Challenges

Biden Executive Order Puts Focus on Domestic Manufacturing of Inventions Created Using Federal Funding

Sens. Tillis and Coons Propose New Legislation Regarding Patentability Under § 101

MetaBirkins Post-Trial Ruling Clarifies Line Between Trademark Infringement and Free Expression and Grants Broad Injunctive Relief

Supreme Court Limits Expression-Based Defenses to Trademark Claims

Top IP, FDA, and Compliance Issues for Medtech Companies Transitioning to Data-Enabled Product Solutions

Utah Bar Association – Intellectual Property Law Summit

FCBA Program on 2023 Patent Law Year in Review

Litigation Financing Demystified: Insights from Funders and Counsel

Contracting Away Your IP Rights: Pitfalls to Avoid With Third Party Partners During Drug Development

Cell and Gene Therapies and Section 112: An Overview of the State of §112 Law and Considerations for Developers of Cell and Gene Therapies

CenterForce's Business Development Summit: Diverse Partners & Associates

California Supreme Court Review: October 2023 (Daily Journal)

Miro acquires Freehand app from InVision

Pharmaceuticals

Life Sciences

Intellectual Property

Complex Litigation & Dispute Resolution

Hatch-Waxman, Biologics and Biosimilars Litigation

Life Sciences Regulatory & Compliance

Litigation